IIR’s Drug Delivery Partnerships is known throughout the industry for providing cutting-edge, thought-provoking commentary from pharmaceutical executives on a range of topics that affect your business. DDP 2013’s line-up of speakers was especially exciting, as the event showcased the always crucial device segment of the industry with a panel of industry leaders. James J. Collins, Vice President of Drug Delivery and Device R&D for Eli Lilly was among those leaders. Mr. Collins is responsible for global design and development of all drug delivery medical devices for Lilly’s pharmaceutical portfolio and is involved in the corporate drug delivery strategy. It is through this lens that he discussed the current challenges in healthcare today, the opportunities for pharma companies to improve patient outcomes and novel drugs for our program, DDP TV.
Topic: Enabling Breakthroughs: Roles Played and Changes for Drugs, Delivery & Devices James Collins, VP, Packaging and Delivery Device Design and Development, Eli Lilly
Don’t forget to save the date! The 2014 Drug Delivery Partnerships event will be taking place on January 27-29, 2014 in beautiful Boca Raton, Florida.
Cheers,
Drug Delivery Partnerships Team
Hey, Nice post, but all still thoughts. So far, nanoparticles can be labeled with receptors and filled with drugs, but often they hurt the whole organism instead of just the cancer cells, and often, the specific receptor for the cancer is not known, or changes for every person. A long way to go... But promising.Thank you!!!
ReplyDelete~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
majakel